Antipsychotic Augmentation for OCD: What Is It? Evidence, When It Is Considered, and Safety
Antipsychotic augmentation for obsessive-compulsive disorder (OCD) means adding an antipsychotic medication to an ongoing serotonin reuptake inhibitor (SRI), usually after standard OCD treatment has produced an inadequate response. It is a specialist pharmacologic strategy for persistent OCD symptoms, not a first-line treatment and not evidence that a person has psychosis. The best-supported agents are risperidone and aripiprazole, but benefit is far from universal and the decision depends as much on previous treatment, exposure and response prevention (ERP), comorbidities, drug interactions, and side-effect risk as on the choice of antipsychotic.
Across randomized trials and meta-analyses, antipsychotic augmentation can reduce OCD symptoms in some adults whose symptoms remain clinically significant despite adequate SRI treatment. Older systematic reviews often summarize the response rate as roughly one in three patients. A 2015 meta-analysis of 14 double-blind randomized placebo-controlled trials found a significant class-level benefit, with the clearest individual evidence for aripiprazole, risperidone, and—on much thinner evidence—haloperidol. A 2026 systematic review and network meta-analysis again supported a class effect while emphasizing that tolerability and evidence quality differ substantially among drugs. (Dold et al., 2015; Shahtou et al., 2026)
The crucial clinical point is where augmentation sits in the treatment sequence. NICE recommends reviewing adherence and adequacy of treatment, offering combined CBT with ERP and an SSRI when either alone has been insufficient, considering another SSRI or clomipramine when needed, and reserving antipsychotic augmentation for later specialist planning after multiple adequate treatment steps. In a major randomized trial, adding ERP to an SRI was markedly more effective than adding risperidone, which is why access to high-quality ERP should be examined before antipsychotic augmentation is treated as the obvious next move. (NICE OCD guideline; Simpson et al., 2013)
This article is for education and evidence review. Prescription decisions, dose changes, and discontinuation require an individual clinical assessment.
What Is Antipsychotic Augmentation for OCD?
“Augmentation” means that a medication already being used for OCD is continued and another treatment is added to improve an incomplete response. In this context, the base treatment is usually an SSRI such as fluoxetine, fluvoxamine, paroxetine, or sertraline, or sometimes the tricyclic SRI clomipramine. The antipsychotic is an adjunct: it is not intended to replace the SRI, and antipsychotic monotherapy is not a standard treatment for OCD. (NICE OCD guideline)
The name of the drug class can be misleading for people with OCD. Antipsychotics were developed and are widely used for psychotic disorders, bipolar disorder, and several other conditions, but the same drugs also have evidence as adjuncts in nonpsychotic conditions. Using risperidone or aripiprazole as an OCD augmenter does not imply that the person has schizophrenia, delusions, or hallucinations. It means a clinician is using a medication with dopamine and serotonin effects to try to strengthen an anti-OCD treatment response.
In the United States, OCD augmentation with risperidone or aripiprazole is off-label. Current U.S. prescribing information for risperidone lists schizophrenia, bipolar mania, and irritability associated with autistic disorder as approved indications, while OCD is not listed. Off-label use is common in medicine when evidence supports a use that is not part of the regulatory label, but it places extra importance on a clear rationale, informed consent, monitoring, and periodic reassessment. (DailyMed risperidone; DailyMed aripiprazole)
Where Does It Fit in OCD Treatment?
Antipsychotic augmentation is best understood as one branch of treatment for persistent symptoms after evidence-based first-line care has been used adequately. OCD often requires longer medication trials than depression, and declaring a medication ineffective too early can create false “treatment resistance.” NICE notes that the therapeutic effect of SSRIs can be delayed for up to 12 weeks and recommends checking regular use, dose, and potential interference from alcohol or substance use when there has been no response. (NICE OCD guideline)
For adults who have not had an adequate response to an SSRI alone or to CBT with ERP alone, NICE recommends multidisciplinary review and combined CBT with ERP plus an SSRI. If combined treatment remains inadequate, another SSRI or clomipramine may be offered. Only after fuller trials of these approaches does NICE place antipsychotic augmentation among specialist options, alongside additional CBT or cognitive therapy. That sequencing matters because augmentation exposes a person to a second medication with its own short- and long-term risks. (NICE OCD guideline)
Other guidelines organize the sequence somewhat differently, but contemporary recommendations converge on the same principle: optimize proven OCD treatment before moving to augmentation. The 2023 Brazilian Research Consortium guideline describes SSRIs at the highest recommended or tolerated doses for 8–12 weeks as first-line pharmacotherapy and identifies low-dose risperidone or aripiprazole as the most evidence-based pharmacologic augmentation options for SSRI-resistant OCD. WFSBP guidance likewise includes antipsychotic augmentation among options for treatment-resistant cases rather than routine first-line care. (Oliveira et al., 2023; Bandelow et al., 2022)
What Counts as an Adequate Trial Before Augmentation?
There is no single universally accepted definition of “treatment-resistant OCD,” and research studies have used different thresholds. That inconsistency is one reason effect estimates should not be translated into a simple prediction for an individual patient. In practice, clinicians usually examine several questions before labeling symptoms resistant: Was the OCD diagnosis carefully established? Was the SRI taken consistently? Was the dose and duration adequate for OCD? Were side effects limiting adherence? Was ERP delivered with sufficient intensity and response prevention rather than only supportive therapy? Were comorbid conditions, substance use, sleep problems, or medical issues interfering with treatment? (NICE OCD guideline; Oliveira et al., 2023)
The distinction between partial response and nonresponse also matters. Augmentation is especially intuitive when an SRI has clearly helped but clinically important obsessions and compulsions remain, because the clinician is trying to preserve a useful base response and add another mechanism. In a complete nonresponse, revisiting the diagnosis, adherence, medication choice, dose, duration, and ERP history may be more informative than simply stacking another medication on top.
A Y-BOCS score can help clinicians quantify severity and change over time, but it is not a stand-alone diagnostic test and it does not determine whether someone should receive an antipsychotic. Trials have also used different response definitions, commonly a 25% or 35% reduction in Y-BOCS. These are research and clinical outcome conventions, not self-treatment thresholds. (Dold et al., 2013; Simpson et al., 2013)
How Strong Is the Evidence?
The evidence is meaningful, but it is smaller and less definitive than the evidence base for first-line SSRIs and ERP. A 2015 update meta-analysis pooled 14 double-blind randomized placebo-controlled trials involving 491 participants with treatment-resistant OCD. Antipsychotic augmentation produced a statistically significant improvement in total Y-BOCS scores versus placebo. In drug-specific analyses, aripiprazole, risperidone, and haloperidol separated from placebo; olanzapine, paliperidone, and quetiapine did not. (Dold et al., 2015)
An earlier meta-analysis of 12 randomized trials involving 394 participants also found that antipsychotic augmentation increased the probability of response, estimating that about one-third of SRI-resistant patients benefited. At that time, risperidone had the most consistent individual evidence. The broader lesson has held up: the class is not uniformly effective, and “antipsychotic augmentation” should not be treated as though every agent were interchangeable. (Dold et al., 2013)
The 2026 systematic review and network meta-analysis expanded the literature to 43 studies, including 22 randomized trials and 21 observational studies. Its pairwise analysis of randomized trials again found a significant class-level reduction in OCD severity. The network ranking favored haloperidol numerically, followed by olanzapine, risperidone, and aripiprazole, but rankings from a sparse network should not be read as a prescribing league table. Haloperidol’s evidence is limited and its tolerability burden is substantial; older RCT-only meta-analysis did not establish olanzapine as consistently effective. The 2026 authors ultimately identified risperidone and aripiprazole as offering the most favorable balance of evidence and tolerability. (Shahtou et al., 2026)
Several limitations run through this literature. Many trials are small. Most are short. Definitions of SRI resistance differ. Doses and prior treatment vary. Head-to-head comparisons between antipsychotics are scarce. Long-term metabolic and movement-disorder outcomes are not captured well by brief efficacy trials. These limitations do not erase the signal of benefit, but they narrow what can responsibly be claimed. (Dold et al., 2015; Shahtou et al., 2026)
Risperidone: Why It Has the Longest Evidence Base
Risperidone is one of the most studied antipsychotic augmenters in OCD. Small placebo-controlled trials in SRI-resistant OCD produced positive findings, and pooled analyses have repeatedly supported efficacy. For example, a 2003 double-blind trial enrolled adults who had failed at least 12 weeks of SRI treatment and found responders among participants receiving risperidone but not placebo. A 2005 trial found that very-low-dose risperidone improved outcomes in a subgroup that had remained refractory after standardized fluvoxamine treatment. (Pallanti et al., 2003; Erzegovesi et al., 2005)
At the same time, risperidone is not a guaranteed next step. The largest direct comparison of medication augmentation with behavioral augmentation produced a strikingly different result: risperidone did not outperform placebo, while ERP produced large improvements. That trial is a reminder that positive meta-analytic averages coexist with substantial individual and study-level variation. (Simpson et al., 2013)
Risperidone also has a distinctive safety profile. Its U.S. label warns about metabolic changes, movement-related adverse effects, and hyperprolactinemia. Persistent prolactin elevation can affect sexual and reproductive function and, when associated with hypogonadism, may contribute to loss of bone density. This makes baseline risk assessment and symptom monitoring important even when the OCD augmentation dose is lower than doses commonly used for schizophrenia. (DailyMed risperidone)
Aripiprazole: Evidence and Differences From Risperidone
Aripiprazole has a different pharmacologic profile from risperidone and has accumulated a comparatively consistent augmentation signal in randomized OCD trials. A 2011 double-blind placebo-controlled study found significant symptom improvement when aripiprazole was added to stable SRI or clomipramine treatment in treatment-resistant OCD, and another randomized trial using 10 mg/day also reported significant Y-BOCS improvement. The 2015 RCT meta-analysis identified aripiprazole as one of the agents that significantly outperformed placebo. (Muscatello et al., 2011; Sayyah et al., 2012; Dold et al., 2015)
Aripiprazole often has less prolactin elevation than risperidone, but its own adverse-effect pattern matters. Akathisia—an uncomfortable sense of inner restlessness with an urge to move—is especially relevant, along with agitation, nausea, insomnia in some patients, and movement-related effects. Like other atypical antipsychotics, aripiprazole carries warnings about hyperglycemia, dyslipidemia, and weight gain, even though average metabolic effects may be smaller than with some other agents. (DailyMed aripiprazole)
Drug interactions can materially change exposure. Fluoxetine and paroxetine, both medications used in OCD, are strong CYP2D6 inhibitors. Current U.S. aripiprazole labeling recommends dose reduction when aripiprazole is given with a strong CYP2D6 inhibitor. This is a concrete reason why an augmentation dose cannot be copied from a study or from another patient’s prescription. (DailyMed aripiprazole interaction)
What About Haloperidol, Quetiapine, Olanzapine, and Paliperidone?
Haloperidol has a positive efficacy signal, but the evidence rests on a much smaller trial base than the evidence for risperidone and aripiprazole. First-generation antipsychotics also have a less favorable movement-disorder profile, including greater concern about extrapyramidal symptoms and tardive dyskinesia. A high numerical ranking in a network meta-analysis therefore does not make haloperidol the routine first choice for OCD augmentation. (Dold et al., 2015; Shahtou et al., 2026)
Quetiapine and olanzapine have produced inconsistent results. In the 2015 RCT meta-analysis, neither separated significantly from placebo on the primary pooled outcome. The 2026 network meta-analysis produced a more favorable numerical estimate for olanzapine, but the literature remains too heterogeneous to treat it as equivalent in evidence to risperidone or aripiprazole. Quetiapine’s evidence was weaker in the recent network as well. (Dold et al., 2015; Shahtou et al., 2026)
Paliperidone has been studied much less and has not developed the same level of support. Newer agents such as brexpiprazole and cariprazine are attracting interest, but current evidence is preliminary and includes small observational cohorts. They should be described as emerging research options rather than established OCD augmentation standards. (Shahtou et al., 2026)
ERP Versus Antipsychotic Augmentation
The most clinically important comparative trial in this area randomized 100 adults with at least moderate OCD despite a therapeutic SRI dose to eight weeks of ERP, risperidone, or placebo while the SRI was continued. ERP was decisively superior. Eighty percent of participants assigned to ERP met the study’s response criterion of at least a 25% Y-BOCS reduction, compared with 23% receiving risperidone and 15% receiving placebo. Forty-three percent of the ERP group achieved minimal symptoms, compared with 13% on risperidone and 5% on placebo. Risperidone did not significantly differ from placebo on the primary outcome. (Simpson et al., 2013)
Six-month follow-up preserved that advantage. Participants originally assigned to ERP had lower OCD severity and were more likely to meet response and minimal-symptom criteria than those assigned to risperidone. A later crossover study also found that ERP helped people who had not responded to prior risperidone or placebo augmentation. (Foa et al., 2015; Carpenter et al., 2016)
This does not mean that risperidone never works; multiple smaller trials and meta-analyses show that it can. It means treatment sequencing matters. If a person has had an adequate SRI trial but has not yet received competent ERP, the evidence strongly supports making ERP access a central part of the next-step discussion before assuming that another medication is the best augmentation. (Dold et al., 2015; Simpson et al., 2013)
Does Antipsychotic Augmentation Work Better When OCD Includes Tics?
Older literature suggested that people with OCD and comorbid tic disorders might have a higher probability of responding to antipsychotic augmentation, particularly to dopamine-blocking agents. A 2006 systematic review found a larger pooled benefit in the tic subgroup. That signal has influenced clinical teaching for years. (Bloch et al., 2006)
The predictor is not reliable enough to use as a rule. Individual randomized trials have not consistently replicated a tic-specific advantage, and the overall evidence base is too small to predict response confidently from tic status alone. Comorbid tics can still affect treatment planning, but they should be one part of a broader assessment rather than a shortcut to augmentation. (McDougle et al., 2000; Bloch et al., 2006)
How Long Is an Augmentation Trial?
Randomized OCD augmentation trials have generally been short, often around six to twelve weeks. Contemporary guidance commonly treats augmentation as a defined trial rather than an open-ended addition. The 2025 clinical practice guideline update describes at least eight weeks as an adequate low-dose antipsychotic augmentation trial, while earlier guideline reviews have recommended stopping within roughly three months when there is no meaningful response. (Arumugham et al., 2026)
That logic is important because risks accumulate while benefit may never appear. Before starting, the clinician and patient can define what improvement would count as meaningful: change in obsessions and compulsions, time consumed, avoidance, family accommodation, functioning, or a clinician-rated Y-BOCS change. If the planned trial does not produce a meaningful benefit, continuing indefinitely exposes the person to medication risk without a clear therapeutic return. (Arumugham et al., 2026)
If augmentation does help, the evidence gives less certainty about how long the antipsychotic should be continued. Long-term controlled OCD data are sparse. Continued treatment therefore calls for periodic reassessment of the benefit, adverse effects, dose, ongoing need, and whether ERP or other interventions can consolidate gains.
What Doses Have Been Studied?
OCD augmentation studies generally use antipsychotic doses that are lower than doses commonly used to treat schizophrenia. A 2025 guideline update gives research-informed examples of risperidone 1–3 mg/day and aripiprazole 5–10 mg/day for augmentation, while individual RCTs have used somewhat different schedules: risperidone trials have included doses from 0.5 mg/day upward, and aripiprazole trials have used 10 mg/day or 15 mg/day. (Arumugham et al., 2026; Pallanti et al., 2003; Muscatello et al., 2011; Sayyah et al., 2012)
These numbers describe the literature; they are not a dosing instruction. The clinically appropriate dose can change with age, liver and kidney function, previous sensitivity, other medications, pharmacogenetic differences, and drug interactions. In OCD specifically, fluoxetine or paroxetine can increase exposure to aripiprazole and risperidone through CYP2D6 inhibition. Current U.S. labeling for both drugs contains interaction guidance, so the medication list has to be reviewed as a system rather than one drug at a time. (DailyMed risperidone interaction; DailyMed aripiprazole interaction)
Safety: What Has to Be Monitored?
The safety question is central because augmentation adds a second long-term-acting psychotropic mechanism to an existing SRI regimen. Antipsychotics differ from one another, but clinically important class-level concerns include weight change, glucose dysregulation, lipid changes, movement symptoms, akathisia, sedation or activation, orthostatic symptoms, and rare severe reactions such as neuroleptic malignant syndrome. Tardive dyskinesia is a potentially persistent movement disorder whose risk becomes increasingly relevant with cumulative exposure. (DailyMed risperidone; DailyMed aripiprazole)
NICE antipsychotic-monitoring guidance for psychotic disorders provides a useful general safety framework: before starting an antipsychotic, clinicians assess weight, waist circumference, pulse and blood pressure, fasting glucose or HbA1c, lipids, prolactin, existing movement disorders, nutritional status, diet, and physical activity. ECG assessment is indicated in specified circumstances such as cardiovascular risk, a product-label requirement, known cardiovascular disease, or inpatient treatment. The exact monitoring plan for an OCD patient should be individualized to the selected drug and the person’s risk profile. (NICE antipsychotic monitoring)
Risperidone deserves particular attention to prolactin-related symptoms and dose-related movement effects. Aripiprazole deserves particular attention to akathisia and activation. Olanzapine has a substantial metabolic burden, while quetiapine can be strongly sedating for some people. These differences help explain why efficacy alone is not enough to choose an augmenter. (DailyMed risperidone; DailyMed aripiprazole)
Akathisia Matters Because It Can Be Misread
Akathisia can feel like internal agitation, an inability to sit still, pacing, or an urgent need to move. In a person with OCD, that experience can be confused with anxiety, medication “activation,” or worsening psychiatric distress. Recognizing the timing and physical quality of the symptom matters because the management question is different from simply increasing treatment for anxiety. (DailyMed aripiprazole)
NICE already advises clinicians to watch for akathisia and restlessness during SSRI treatment. Antipsychotic augmentation adds another potential source of movement-related restlessness, especially with aripiprazole. New marked restlessness after a medication change deserves prompt clinical review rather than being normalized as something the patient must simply tolerate. (NICE OCD guideline; DailyMed aripiprazole)
Metabolic and Hormonal Effects Are Not Only Long-Term Abstract Risks
Weight, glucose, lipids, and prolactin are often discussed as laboratory monitoring issues, but their consequences are practical. Weight gain can affect cardiovascular risk, sleep, mobility, adherence, and body image. Hyperglycemia can become medically significant. Hyperprolactinemia can contribute to menstrual changes, sexual dysfunction, galactorrhea, reduced gonadal hormones, and bone-density concerns when prolonged. (DailyMed risperidone; DailyMed aripiprazole)
Because OCD can require long-term treatment, a small short-term improvement has to be weighed against the burden of maintaining an additional medication. The decision becomes more favorable when the benefit is clear, function improves, the dose is modest, monitoring is feasible, and adverse effects remain acceptable. It becomes less favorable when benefit is ambiguous and side effects or metabolic changes accumulate.
Drug Interactions With Common OCD Medications
The interaction between augmenters and the existing SRI deserves explicit attention. Fluoxetine and paroxetine inhibit CYP2D6. Current risperidone labeling reports that both can substantially increase risperidone exposure and advises dose titration accordingly. Current aripiprazole labeling likewise recommends dose reduction when a strong CYP2D6 inhibitor such as fluoxetine or paroxetine is co-administered. (DailyMed risperidone interaction; DailyMed aripiprazole interaction)
That does not make these combinations inherently inappropriate; such combinations are used clinically. It means the “same” milligram dose can produce different exposure depending on the companion antidepressant. Other medications and enzyme inducers or inhibitors can alter exposure as well. A complete medication and supplement review is therefore part of safe augmentation.
Does Taking an Antipsychotic Mean OCD Has Become Psychosis?
No. OCD and psychotic disorders are different diagnostic categories, and the pharmacologic use of an antipsychotic does not determine the diagnosis. Antipsychotics are used across multiple conditions because medications act on receptor systems rather than on diagnostic labels.
OCD can also vary in insight. Some people recognize clearly that their obsessional fears are excessive; others have much less insight. Poor insight can complicate assessment, but the diagnostic task remains to determine the structure of the symptoms: intrusive obsessions, compulsions or mental rituals, the relationship between beliefs and rituals, and the presence or absence of genuinely psychotic symptoms. Medication class names cannot substitute for that assessment.
Who May Be a Reasonable Candidate for Specialist Augmentation?
The evidence most directly applies to adults with a well-established OCD diagnosis who remain substantially symptomatic after an adequate SRI trial and who have already received, or had a meaningful opportunity to receive, evidence-based ERP. A clinician may consider augmentation when the base SRI has produced partial benefit worth preserving, residual symptoms still impair daily life, and the likely benefit outweighs the individual medication risks. (Oliveira et al., 2023; NICE OCD guideline)
The threshold should be higher when metabolic disease, prior severe akathisia or extrapyramidal symptoms, hyperprolactinemia, relevant cardiac risk, complex polypharmacy, pregnancy, breastfeeding, frailty, or other medical factors change the safety equation. These circumstances do not yield a universal answer; they make drug selection and monitoring more individualized.
Children and Adolescents
Most antipsychotic augmentation evidence in OCD comes from adults. The adult evidence should not be copied directly into pediatric treatment. NICE’s pathway for children and young people emphasizes CBT with ERP involving family or carers and carefully monitored SSRI treatment; when that combination is unsuccessful or poorly tolerated, another SSRI or clomipramine may be considered with specialist involvement. (NICE OCD guideline)
Pediatric OCD also raises additional questions about growth, weight, metabolic effects, prolactin, movement disorders, schooling, and family accommodation. Antipsychotic augmentation in a child or adolescent therefore belongs in specialist child and adolescent psychiatric care with a diagnosis-specific rationale and monitoring plan.
What Happens if Augmentation Does Not Work?
A failed antipsychotic trial is information, not proof that the OCD is untreatable. The next step may be to stop an ineffective augmenter, reassess the base medication, intensify or redesign ERP, address treatment-interfering avoidance or family accommodation, reconsider a different SRI or clomipramine when appropriate, or seek a specialist OCD service for a structured treatment-resistance review. (Bandelow et al., 2022; Arumugham et al., 2026)
Other pharmacologic augmentation strategies have been studied, including glutamatergic agents and 5-HT3 antagonists, but their evidence quality and guideline status vary. Neuromodulation and neurosurgical approaches such as transcranial magnetic stimulation or deep brain stimulation belong much later in the pathway and are reserved for selected cases. The existence of those options does not justify skipping the fundamentals of diagnosis, adequate SRI treatment, and ERP.
What Happens if Augmentation Works?
When symptoms improve meaningfully, the task shifts from “Does this work?” to “How do we preserve the benefit with the least treatment burden?” That includes continued measurement of OCD symptoms and functioning, active monitoring for adverse effects, attention to metabolic and movement outcomes, and a plan for ERP or other behavioral work that can strengthen recovery.
Because long-term randomized evidence for antipsychotic augmentation in OCD is limited, indefinite continuation should not happen by inertia. The ongoing rationale should remain visible: what changed after the augmenter was added, what adverse effects appeared, what other treatments are active, and what would justify maintaining, reducing, changing, or eventually discontinuing the antipsychotic under medical supervision.
Questions to Discuss With a Prescriber
A useful consultation focuses on the treatment sequence rather than only the drug name. Has the current SRI trial been long enough and taken consistently? Has the dose been optimized safely? Has ERP been delivered by someone trained in OCD, and was response prevention actually practiced? Is there a reason to switch the SRI or consider clomipramine before augmentation? What improvement would count as success, and by what date will the trial be reviewed?
The safety half of the discussion is equally concrete. Which adverse effects are most relevant for this person? What baseline measurements or laboratory tests are needed? Could fluoxetine, paroxetine, or another medication change antipsychotic exposure? What symptoms should trigger an earlier review? If the augmenter does not help, how will it be stopped? A defined plan makes augmentation a controlled therapeutic experiment rather than a medication that silently becomes permanent.
Frequently Asked Questions
The questions below address common search concerns about antipsychotic augmentation. They are educational and cannot determine whether a specific person should start, stop, or change prescription medication.
Is antipsychotic augmentation a first-line treatment for OCD?
No. First-line OCD care centers on ERP-based CBT and serotonin reuptake inhibitors. Antipsychotic augmentation is generally considered after an adequate first-line treatment sequence has left clinically significant symptoms. (NICE OCD guideline; Arumugham et al., 2026)
Which antipsychotics have the best evidence for OCD augmentation?
Risperidone and aripiprazole have the most consistent evidence across randomized trials, meta-analyses, and contemporary guidelines. Haloperidol has a positive but much thinner evidence base and a less favorable tolerability profile. Evidence for quetiapine and olanzapine is inconsistent, and evidence for paliperidone and newer agents is more limited. (Dold et al., 2015; Shahtou et al., 2026)
How likely is it to work?
A common summary from the older randomized literature is that roughly one-third of SRI-resistant patients improve with antipsychotic augmentation. That is a population average, not an individual probability. Response depends on how treatment resistance was defined, the augmenter, prior treatment, and the outcome threshold used. (Dold et al., 2013; Bloch et al., 2006)
Is risperidone better than aripiprazole?
The evidence does not establish a universally superior choice. Both have support. Risperidone has a longer OCD trial history and more concern about prolactin elevation; aripiprazole has consistent efficacy signals and more concern about akathisia or activation. Medication history, interactions, comorbidities, and adverse-effect priorities often determine the practical choice. (Dold et al., 2015; DailyMed risperidone; DailyMed aripiprazole)
Can an antipsychotic be used alone for OCD?
Antipsychotic monotherapy is not a standard OCD treatment. NICE specifically advises that antipsychotics should not normally be used as monotherapy for OCD. The evidence discussed here concerns augmentation of an ongoing SRI or clomipramine regimen. (NICE OCD guideline)
Should ERP be tried before antipsychotic augmentation?
For many adults, yes. NICE places combined CBT with ERP plus an SSRI before later specialist antipsychotic augmentation, and the best direct randomized comparison found ERP substantially more effective than risperidone as an SRI augmentation strategy. (NICE OCD guideline; Simpson et al., 2013)
How quickly should benefit appear?
OCD augmentation trials are usually measured over several weeks rather than a few days. Many studies have used six- to twelve-week designs, and contemporary guidance often treats around eight weeks as an adequate trial. The planned review point should be agreed with the prescriber before treatment begins. (Arumugham et al., 2026)
Can fluoxetine or paroxetine interact with risperidone or aripiprazole?
Yes. Both fluoxetine and paroxetine are strong CYP2D6 inhibitors and can increase exposure to these antipsychotics. Current U.S. prescribing information includes dose-adjustment or titration guidance for these combinations. This is one reason augmentation dosing must be individualized by a prescriber. (DailyMed risperidone interaction; DailyMed aripiprazole interaction)
Does an antipsychotic prescription mean I have psychosis?
No. The reason a medication is prescribed and the diagnosis are separate questions. Risperidone and aripiprazole have uses outside psychotic disorders, and in OCD they may be prescribed as adjuncts to reduce persistent obsessions and compulsions.
What are the most important safety issues?
They depend on the drug, but major considerations include metabolic changes, weight, glucose and lipids, movement symptoms and akathisia, sedation or activation, prolactin effects with risperidone, cardiovascular risk in selected patients, drug interactions, and rare serious reactions. Monitoring should be tailored to the specific agent and the person’s medical history. (NICE antipsychotic monitoring; DailyMed risperidone; DailyMed aripiprazole)
The Bottom Line
Antipsychotic augmentation is a legitimate evidence-based option for a defined subgroup of adults with persistent OCD, especially after an adequate SRI trial and appropriate ERP have failed to produce sufficient improvement. The best-supported agents are risperidone and aripiprazole, and the expected benefit is meaningful for some patients but absent for many. (Dold et al., 2015; NICE OCD guideline)
Its place in care is therefore precise: specialist, measured, time-limited at the outset, and tied to a clear treatment target. ERP should not be displaced by medication convenience, and “treatment resistant” should not be declared before the fundamentals have been verified. When augmentation is used, the same rigor applied to efficacy should be applied to safety—baseline risk assessment, interaction review, metabolic and movement monitoring, and an explicit decision point about whether the drug has earned a place in long-term treatment.